Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2025

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2025-12-22: Form 6-K; Period of report 2025-12-22; Description DIRECTOR/PDMR SHAREHOLDING; Document a3725m.htm.
  • 2025-12-22: Form 6-K; Period of report 2025-12-22; Description ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC; Document a3788m.htm.
  • 2025-12-22: Form 6-K; Period of report 2025-12-22; Description UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB; Document a3786m.htm.
  • 2025-12-19: Form 6-K; Period of report 2025-12-19; Description DIRECTOR/PDMR SHAREHOLDING; Document a2063m.htm.
FiledFormPeriod of reportDescriptionDocument
2025-12-226-K2025-12-22DIRECTOR/PDMR SHAREHOLDINGa3725m.htm
2025-12-226-K2025-12-22ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BCa3788m.htm
2025-12-226-K2025-12-22UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIBa3786m.htm
2025-12-196-K2025-12-19DIRECTOR/PDMR SHAREHOLDINGa2063m.htm
2025-12-166-K2025-12-16SUBCUTANEOUS SAPHNELO APPROVED IN EUa655l.htm
2025-12-166-K2025-12-16ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BCa6719l.htm
2025-12-046-K2025-12-04HOLDING(S) IN COMPANYa3053k.htm
2025-12-016-K2025-12-01BLOCK LISTING INTERIM REVIEWa6866j.htm
2025-12-016-K2025-12-01TOTAL VOTING RIGHTSa6944j.htm
2025-11-266-K2025-11-26IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCERa9865i.htm
2025-11-246-K2025-11-24ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLANDa6308i.htm
2025-11-206-K2025-11-20KOSELUGO (SELUMETINIB) APPROVED IN THE USa2653i.htm
2025-11-176-K2025-11-17HOLDING(S) IN COMPANYa8336h1.htm
2025-11-146-K2025-11-14DIRECTOR/PDMR SHAREHOLDINGa6121h.htm
2025-11-106-K2025-11-10DIRECTOR/PDMR SHAREHOLDINGa9097g.htm
2025-11-066-K2025-11-069M AND Q3 2025 RESULTSa4030g.htm
2025-11-036-K2025-11-03RESULT OF GENERAL MEETINGa9801f.htm
2025-11-036-K2025-11-03TOTAL VOTING RIGHTSa7883f.htm
2025-11-036-K2025-11-03FORM 6-Ktm2529889d1_6k.htm
2025-10-286-K2025-10-28DIRECTOR DECLARATIONa9943e.htm
2025-10-286-K2025-10-28KOSELUGO (SELUMETINIB) APPROVED IN THE EUa0174f.htm
2025-10-226-K2025-10-22TEZSPIRE APPROVED IN EU FOR CRSWNPa2961e.htm
2025-10-206-K2025-10-20US FDA APPROVES TEZSPIRE IN CRSWNPa9315d.htm
2025-10-206-K2025-10-20POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELOa9156d.htm
2025-10-146-K2025-10-14AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICESa9731c.htm
2025-10-076-K2025-10-07BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIALa2843c.htm
2025-10-066-K2025-10-06DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02a1092c.htm
2025-10-016-K2025-10-01TOTAL VOTING RIGHTSa5115b.htm
2025-09-296-K2025-09-29ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05a1100b.htm
2025-09-296-K2025-09-29AZN HARMONISES LISTING STRUCTUREa1788b.htm
2025-09-296-K2025-09-296-Ktm2526326-11_6k.htm
2025-09-256-K2025-09-25DIRECTOR/PDMR SHAREHOLDINGa8844a.htm
2025-09-226-K2025-09-22KOSELUGO RECOMMENDED FOR EU APPROVALa2200a.htm
2025-09-226-K2025-09-22TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNPa2198a.htm
2025-09-176-K2025-09-17SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SCa6053z.htm
2025-09-176-K2025-09-17UPDATE ON RESOLUTE PHASE III TRIALa6048z.htm
2025-09-026-K2025-09-02TOTAL VOTING RIGHTSa3337x.htm
2025-08-286-K2025-08-28HOLDING(S) IN COMPANYa0720x.htm
2025-08-266-K2025-08-26HOLDING(S) IN COMPANYa6775w.htm
2025-08-216-K2025-08-21HOLDING(S) IN COMPANYa2511w.htm
2025-08-186-K2025-08-18DIRECTOR/PDMR SHAREHOLDINGa7666v.htm
2025-08-156-K2025-08-15HOLDING(S) IN COMPANYa5241v.htm
2025-08-126-K2025-08-12HOLDING(S) IN COMPANYa0142v.htm
2025-08-016-K2025-08-01TOTAL VOTING RIGHTSa6194t.htm
2025-07-296-K2025-06-30FORM 6-Kazn-20250630x6k.htm
2025-07-246-K2025-07-24GEFURULIMAB NANOBODY MET PHASE III ENDPOINTSa3269s.htm
2025-07-226-K2025-07-22ASTRAZENECA PLANS TO INVEST $50BN IN THE USa9509r.htm
2025-07-166-K2025-07-16UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSISa2015r.htm
2025-07-146-K2025-07-14BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIALa9003q.htm
2025-07-076-K2025-07-07IMFINZI APPROVED IN THE EU FOR BLADDER CANCERa7036p.htm
2025-07-016-K2025-07-01TOTAL VOTING RIGHTSa0819p.htm
2025-06-246-K2025-06-24DATROWAY APPROVED IN US FOR EGFRM LUNG CANCERa0674o.htm
2025-06-136-K2025-06-13ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPCa6592m.htm
2025-06-126-K2025-06-12DIRECTOR/PDMR SHAREHOLDINGa4851m.htm
2025-06-066-K2025-06-06FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLLa7065l.htm
2025-06-026-K2025-06-02BLOCK LISTING INTERIM REVIEWa9992k.htm
2025-06-026-K2025-06-02TOTAL VOTING RIGHTSa9988k.htm
2025-05-276-K2025-05-27IMFINZI RECOMMENDED IN EU FOR BLADDER CANCERa0471k.htm
2025-05-236-K2025-05-23DIRECTOR/PDMR SHAREHOLDINGa8814j.htm
2025-05-216-K2025-05-21DIRECTOR DECLARATIONa4894j.htm
2025-05-206-K2025-05-20ACQUISITION OF ESOBIOTEC COMPLETEDa3029j.htm
2025-05-096-K2025-05-09IMFINZI IMPROVED DFS IN EARLY BLADDER CANCERa9743h.htm
2025-05-076-K2025-05-07ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCERa5800h.htm
2025-05-066-K2025-05-06CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCLa4568h.htm
2025-05-026-K2025-05-02BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALSa1484h.htm
2025-05-016-K2025-05-01DIRECTOR/PDMR SHAREHOLDINGa1151h.htm
2025-05-016-K2025-05-01TOTAL VOTING RIGHTSa9064g.htm
2025-04-296-K2025-04-29FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLLa4906g.htm
2025-04-296-K2025-04-29UPDATE ON CAPITELLO-280 PHASE III TRIALa5133g.htm
2025-04-296-K2025-04-291ST QUARTER RESULTSa5242g.htm
2025-04-226-K2025-04-22ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBCa6358f.htm
2025-04-116-K2025-04-11RESULT OF AGMa7730e.htm
2025-04-046-K2025-04-04IMFINZI APPROVED IN EU FOR AEGEANa5497d.htm
2025-04-046-K2025-04-04ENHERTU APPROVED IN EU IN POST-ET BREAST CANCERa5798d.htm
2025-04-016-K2025-04-01TOTAL VOTING RIGHTSa0180d.htm
2025-03-316-K2025-03-31CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCLa7993c.htm
2025-03-316-K2025-03-31IMFINZI APPROVED IN THE US FOR BLADDER CANCERa8120c.htm
2025-03-216-K2025-03-21AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURINGa6965b.htm
2025-03-176-K2025-03-17ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINTa9035a.htm
2025-03-176-K2025-03-17IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLCa9033a.htm
2025-03-176-K2025-03-17ASTRAZENECA TO ACQUIRE ESOBIOTECa9028a.htm
2025-03-126-K2025-03-12HOLDING(S) IN COMPANYa4492a.htm
2025-03-076-K2025-03-07DIRECTOR/PDMR SHAREHOLDINGa8569z.htm
2025-03-076-K2025-03-07NOTICE OF AGMa8473z.htm
2025-03-076-K2025-03-07IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCERa8006z.htm
2025-03-076-K2025-03-07FORM 6-Ktm257801d1_6k.htm
2025-03-066-K2025-03-06DIRECTOR/PDMR SHAREHOLDINGa6846z.htm
2025-03-056-K2025-03-05DIRECTOR/PDMR SHAREHOLDINGa5122z.htm
2025-03-036-K2025-03-03TOTAL VOTING RIGHTSa9708y.htm
2025-03-036-K2025-03-03IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEANa9395y.htm
2025-02-286-K2025-02-28ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCERa9301y.htm
2025-02-266-K2025-02-26CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCERa4479y.htm
2025-02-196-K2025-02-19FILING OF FORM 20-F WITH SECa5991x.htm
2025-02-186-K2025-02-18HOLDING(S) IN COMPANYa5539x.htm
2025-02-186-K2025-02-18ANNUAL FINANCIAL REPORTa4239x.htm
2025-02-186-K2025-02-18DIRECTORATE CHANGEa4044x.htm
2025-02-186-K2025-02-18FORM 6-Ktm251208d3_6k.htm
2025-02-066-K2025-02-06FINAL RESULTSa1107w.htm
2025-02-036-K2025-02-03TOTAL VOTING RIGHTSa7256v.htm
2025-02-036-K2025-02-03IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLCa5235v.htm
Advertisement